What happened
Clinical-stage biotech Aligos Therapeutics (ALGS -4.54%) had some bad news to report on Thursday. As a result, unforgiving investors sent the company's stock down by almost 57%, making it one of the sector's steepest decliners today.
So what
Biotechs without any commercialized products are heavily dependent on the results of the clinical trials for their pipeline programs. This was the issue with Aligos on Thursday; in the morning the company divulged that it is halting the further development of its experimental drug ALG-010133, which targets chronic hepatitis B (CHB).
Image source: Getty Images.
The decision was made based on data from a phase 1 study of the drug, which demonstrated that with ALG-010133, "at the projected efficacious dose ... there is no meaningful [hepatitis B surface antigen] reduction" in patients with the disease.
"We are disappointed that the antiviral activity data from this study indicate that ALG-010133 cannot meaningfully contribute to achieving functional cures in CHB," Aligos CEO Lawrence Blatt said.
"Hepatitis B is a very challenging virus that will likely require combination regimens involving distinct mechanisms of action in order to achieve functional cure," he added.
Now what
In its press release admitting defeat, Aligos hastened to point out that it has numerous other treatments in its pipeline.
The young biotech, which was founded in 2018 and listed on the stock exchange in 2020, will continue to focus on its efforts to combat hepatitis B and other liver diseases, in addition to various viral infections. The withdrawal of ALG-010133, however, is a tough blow that the clearly still-ambitious company will need to find a way to recover from.
